Terms: = Breast cancer AND MYCL, LMYC, 4610, MYCL1, ENSG00000116990 AND Treatment
11 results:
1. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.
Bauer TM; Moore KN; Rader JS; Simpkins F; Mita AC; Beck JT; Hart L; Chu Q; Oza A; Tinker AV; Imedio ER; Kumar S; Mugundu G; Jenkins S; Chmielecki J; Jones S; Spigel D; Fu S
Target Oncol; 2023 Jul; 18(4):517-530. PubMed ID: 37278879
[TBL] [Abstract] [Full Text] [Related]
2. Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer.
Guo Q; Lan T; Lu Y; Hu Z; Xu H; Wang X; Shao X; Fu X
Biomol Biomed; 2023 May; 23(3):502-509. PubMed ID: 36408954
[TBL] [Abstract] [Full Text] [Related]
3. Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations.
Li K; Cao L; Li C; Wu J; Chen B; Zhang G; Li X; Wen L; Jia M; Wei G; Lin J; Li Y; Zhang Y; Mok H; Ren C; Wang Y; Qi X; Guo L; Che Y; Liao N
Cancer Med; 2023 Mar; 12(5):5195-5208. PubMed ID: 36404592
[TBL] [Abstract] [Full Text] [Related]
4. Effectiveness of preoperative stretchings on postoperative shoulder function in patients undergoing mastectomy.
Fatima T; Shakoor A; Ilyas M; Safdar M; Majeed S
J Pak Med Assoc; 2022 Apr; 72(4):625-628. PubMed ID: 35614590
[TBL] [Abstract] [Full Text] [Related]
5. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
[TBL] [Abstract] [Full Text] [Related]
6. Multiple primary non-breast tumors in breast cancer survivors.
Corso G; Veronesi P; Santomauro GI; Maisonneuve P; Morigi C; Peruzzotti G; Intra M; Sacchini V; Galimberti V
J Cancer Res Clin Oncol; 2018 May; 144(5):979-986. PubMed ID: 29502170
[TBL] [Abstract] [Full Text] [Related]
7. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract] [Full Text] [Related]
8. CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.
Hertz DL; Motsinger-Reif AA; Drobish A; Winham SJ; McLeod HL; Carey LA; Dees EC
Breast Cancer Res Treat; 2012 Jul; 134(1):401-10. PubMed ID: 22527101
[TBL] [Abstract] [Full Text] [Related]
9. Clinical profiles predict early nonadherence to adjuvant endocrine treatment in a prospective breast cancer cohort.
Markkula A; Hietala M; Henningson M; Ingvar C; Rose C; Jernström H
Cancer Prev Res (Phila); 2012 May; 5(5):735-45. PubMed ID: 22401981
[TBL] [Abstract] [Full Text] [Related]
10. An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer.
Morrow PK; Murthy RK; Ensor JD; Gordon GS; Margolin KA; Elias AD; Urba WJ; Weng DE; Rugo HS; Hortobagyi GN
Cancer; 2012 Sep; 118(17):4098-104. PubMed ID: 22281842
[TBL] [Abstract] [Full Text] [Related]
11. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group.
Zhong L; Shen H; Huang C; Jing H; Cao D
Toxicol Appl Pharmacol; 2011 Aug; 255(1):40-7. PubMed ID: 21640744
[TBL] [Abstract] [Full Text] [Related]
